

BIOMARIN PHARMACEUTICAL INC

Form 8-K

February 24, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **February 21, 2003**

BioMarin Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of

incorporation or organization)

000-26727

(Commission File Number)

68-0397820

(IRS Employer

Identification No.)

371 Bel Marin Keys Boulevard, Suite 210, Novato, California

(Address of principal executive offices)

94949

(Zip Code)

Registrant's telephone number, including area code: **(415) 884-6700**

Not Applicable

(Former name or former address, if changed since last report)

Item 5. Other Events.

On February 21, 2003, BioMarin Pharmaceutical Inc. (the Registrant), together with its joint venture partner Genzyme General, issued a press release regarding the issuance by the Committee for Proprietary Medicinal Products (CPMP) of the European Union of a positive opinion on the company's marketing application for Aldurazyme. The Registrant's press release issued on February 21, 2003 is attached hereto as Exhibit 99.1.

Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.

- (a) Financial Statements of Business Acquired.

Not Applicable.

- (b) Pro Forma Financial Information.

Not Applicable.

- (c) Exhibits.

Exhibit 99.1 Press Release of the Registrant dated February 21, 2003.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc.,

a Delaware corporation

Date: February 21, 2003

By:

/s/ LOUIS DRAPEAU

Louis Drapeau

Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release of the Registrant dated February 21, 2003.